| 1 |
Solubility measurement of a chemotherapeutic agent (Imatinib mesylate) in supercritical carbon dioxide: Assessment of new empirical model
Sodeifian G, Razmimanesh F, Sajadian SA
Journal of Supercritical Fluids, 146, 89, 2019 |
| 2 |
Imatinib mesylate elicits extracellular signal-related kinase (ERK) activation and enhances the survival of gamma-irradiated epithelial cells
Lee J, Ko J, Kim HJ, Im H, Kim EJ, Yi JY
Biochemical and Biophysical Research Communications, 506(4), 939, 2018 |
| 3 |
Cytoprotective effect of imatinib mesylate in non-BCR-ABL-expressing cells along with autophagosome formation
Ohtomo T, Miyazawa K, Naito M, Moriya S, Kuroda M, Itoh M, Tomoda A
Biochemical and Biophysical Research Communications, 391(1), 310, 2010 |
| 4 |
Imatinib mesylate inhibits platelet derived growth factor stimulated proliferation of rheumatoid synovial fibroblasts
Sandler C, Joutsiniemi S, Lindstedt KA, Juutilainen T, Kovanen PT, Eklund KK
Biochemical and Biophysical Research Communications, 347(1), 31, 2006 |
| 5 |
Differential tyrosine phosphorylation of leukemic cells during apoptosis as a result of treatment with imatinib mesylate
Park J, Kim S, Oh C, Yoon SS, Lee D, Kim Y
Biochemical and Biophysical Research Communications, 336(3), 942, 2005 |
